# The SPECTRA Study

> **NCT00537667** · PHASE2 · TERMINATED · sponsor: **Amgen** · enrollment: 22 (actual)

## Conditions studied

- Rheumatoid Arthritis

## Interventions

- **DRUG:** anakinra
- **DRUG:** anakinra and PEG sTNF-R1

## Key facts

- **NCT ID:** NCT00537667
- **Lead sponsor:** Amgen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2001-08
- **Primary completion:** 2003-03
- **Final completion:** 2003-06
- **Target enrollment:** 22 (ACTUAL)
- **Why stopped:** The safety profile of combination therapy became unacceptable.
- **Last updated:** 2009-11-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00537667

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00537667, "The SPECTRA Study". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT00537667. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*